DYNAVAX TECHNOLOGIES CORP (DVAX)

US2681582019 - Common Stock

12.41  0 (0%)

After market: 12.41 0 (0%)

News Image
a month ago - Dynavax Technologies

Dynavax to Present at TD Cowen's 44th Annual Health Care Conference

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

News Image
a month ago - The Motley Fool

Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript

DVAX earnings call for the period ending December 31, 2023.

News Image
a month ago - Seeking Alpha

Dynavax GAAP EPS of $0.00 beats by $0.01, revenue of $55.6M beats by $2.87M (NASDAQ:DVAX)

Dynavax reported better-than-expected Q4 earnings with a beat in EPS and revenue.

News Image
a month ago - Dynavax Technologies

Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

News Image
2 months ago - Dynavax Technologies

Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative...

News Image
3 months ago - The Motley Fool

Why Vera Therapeutics Stock Soared by 22% This Week

Executive changes and a bullish analyst take combined to boost sentiment on the company.

News Image
3 months ago - InvestorPlace

3 Stocks Set to Soar 68% to 200% Higher

Analyst stock picks for outsized growth potential mean these companies should handily outperform the market averages.

News Image
3 months ago - Seeking Alpha

Dynavax reports 46% Y/Y increase in HEPLISAV-B vaccine net product revenue (NASDAQ:DVAX)

Dynavax Technologies reports strong growth in Q4 2023 with HEPLISAV-B vaccine revenue of $51M, representing a YoY increase of 46%.

News Image
3 months ago - Dynavax Technologies

Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

News Image
4 months ago - Dynavax Technologies

Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

News Image
5 months ago - The Motley Fool

Dynavax Technologies (DVAX) Q3 2023 Earnings Call Transcript

DVAX earnings call for the period ending September 30, 2023.

News Image
5 months ago - Dynavax Technologies

Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

News Image
5 months ago - Dynavax Technologies

Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative...

News Image
5 months ago - Dynavax Technologies

Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

News Image
7 months ago - Dynavax Technologies

Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

News Image
8 months ago - Investor's Business Daily

Dynavax Technologies Stock Sees Renewed Technical Strength

Dynavax Technologies shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84.

News Image
8 months ago - The Motley Fool

Dynavax Technologies (DVAX) Q2 2023 Earnings Call Transcript

DVAX earnings call for the period ending June 30, 2023.

News Image
8 months ago - Seeking Alpha

Dynavax GAAP EPS of $0.03 beats by $0.12, revenue of $60.25M beats by $11.87M (NASDAQ:DVAX)

Dynavax press release (DVAX): Q2 GAAP EPS of $0.03 beats by $0.12.Revenue of $60.25M (-76.5% Y/Y) beats by $11.87M.2023 FINANCIAL GUIDANCEFull year 2023 financial guidance has...

News Image
8 months ago - Dynavax Technologies

Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

News Image
8 months ago - Dynavax Technologies

Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative...

News Image
10 months ago - InvestorPlace

The 7 Best Stocks Under $15 to Buy in June 2023

While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount.

News Image
10 months ago - Dynavax Technologies

Dynavax to Present at Upcoming Investor Conferences

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...